Portal de Periódicos da CAPES

Future Trials of Antiplatelet Agents in Cardiac Ischemia

2001; Massachusetts Medical Society; Volume: 344; Issue: 25 Linguagem: Inglês

10.1056/nejm200106213442509

1533-4406

Douglas C. Throckmorton,

Coronary Interventions and Diagnostics

During the past 10 years there has been a revolution in the management of acute coronary syndromes, which include unstable angina and non–Q-wave myocardial infarction, and reductions in the rate of adverse events after percutaneous coronary revascularization. Physicians today use a wealth of newly developed drug therapies, including low-molecular-weight heparins, thrombin inhibitors, and inhibitors of platelet activation.1,2 Among these therapies, intravenous agents that block the final common pathway for platelet activation, called glycoprotein IIb/IIIa inhibitors, have been studied and approved for use in patients with acute coronary syndromes and in those undergoing percutaneous coronary revascularization. Since 1993, three glycoprotein . . .